Maternal and Neonatal Tetanus Elimination by Yes, We Can! Global Immunization Meeting 18 th February 2009

Similar documents
Overview of Measlescontaining. through UNICEF. Overview of [VACCINE] through UNICEF

Global Immunization Vision and Strategies (GIVS) Vaccine Tender , Pretender Meeting, Copenhagen December 2008

Table 1: Basic information 2017

Table 1: Basic information Total population 25,030, (per 100,000 LB) Division/Province/State/Region 11. District 210

USAID Progress: The U.S. National Vaccine Plan of 1994

Harnessing the power of vaccines using the public and private sector: A 21 st century model for international development

Table 1: Basic information (per 1,000 LB) 42.4 (per 1,000 LB) 49.7 (per 1,000 LB) 215 (per 100,000 LB)

Expanded Programme on Immunization (EPI)

Expanded Programme on Immunization (EPI)

Debriefing on the External Retrospective Evaluation of ACSD

Global Immunization Overview. Thomas Cherian Expanded Programme on Immunization WHO, Geneva

Diphtheria Outbreak Response Cox s Bazar Bangladesh

Measles and Rubella Global Update SAGE 19 October 2017

Total population 1,212,110. Live births (LB) 43,924. Children <1 year 40,351. Children <5 years 192,340. Children <15 years 510,594

Expanded Programme on Immunization (EPI)

Table 1: Basic information ,000, (per 1,000 LB) 34.6 (per 1,000 LB) 174 (per 100,000 LB) District 712.

Expanded Programme on Immunization (EPI)

Global Update of the 2010 GIVS Goals

Total population 20,675,000. Live births (LB) 349,715. Children <1 year 346,253. Children <5 years 1,778,050. Children <15 years 5,210,100

Draft Summary Report on the

WHO VACCINE SUPPLY & QUALITY SUPPORT FOR NATIONAL IMMUNIZATION PROGRAMMES

Total population 24,759,000. Live births (LB) 342,458. Children <1 year 337,950. Children <5 years 1,698,664. Children <15 years 5,233,093

Dr. Collins Tabu KPA Conference, 26 th April 2018 Mombasa, Kenya

Decade of Vaccines Global Vaccine Action Plan. GVAP Secretariat report 2015 Update actions on taken by the secretariat in response to previous reports

Vaccine Preventable Disease Surveillance: Overview. Thomas Cherian, WHO

2010 global TB trends, goals How DOTS happens at country level - an exercise New strategies to address impediments Local challenges

Immunization Update & focus on meningococcal vaccine PART 1

Launch of a supplement in Health Policy and Planning. Dr. Joy Lawn Mary Kinney Anne Pfitzer On behalf of the team

The epidemiology of tuberculosis

Prioritizing Emergency Polio Eradication Activities

Thank you for joining, the M&RI webinar will begin shortly

Reduction of child and maternal mortality in South-East Asia Region WHO-SEARO. UNESCAP Forum, New Delhi: 17 Feb 2012

The Gates Challenge. Bill Gates Commencement Address Harvard University Class of 2007

Total population 1,265,308,000. Live births (LB) 27,016,000. Children <1 year 25,928,200. Children <5 years 23,818,000. Children <15 years 25,639,000

Update on polio vaccine supply & forecast

The WHO Global Project on anti-tb drug resistance surveillance: background, objectives, achievements, challenges, next steps

7.5 South-East Asian Region: summary of planned activities, impact and costs

Strategies to Control Pneumonia and Diarrhoea: Tackling the deadliest diseases for the world s poorest children

Aboubacar Kampo Chief of Health UNICEF Nigeria

POLIO ERADICATION AND POST-CERTIFICATION STRATEGY

Objective 2 Strengthening Routine Immunization, IPV introduction and the topv-bopv switch

Task Force on Immunization (TFI) in Africa 14 th Annual Meeting. And. Africa Regional Inter-Agency Coordination Committee (ARICC) 13 th Annual Meeting

The State of Measles and Rubella in the WHO European Region

Progress reports on selected Regional Committee resolutions:

Pneumococcal Vaccine Introductions Dr. Carsten Mantel WHO/FCH/IVB/EPI

Partnership That Gives Dividends.

Driving access to medicine

Global reductions in measles mortality and the risk of measles resurgence

Update on Polio Vaccine Supply

PLANNING & EVALUATION WORKBOOK

CANCER FACT SHEETS: BREAST CANCER

ANNEX Page. AFR/RC61/11 4 July 2011 ORIGINAL: ENGLISH REGIONAL COMMITTEE FOR AFRICA

MAPS ON GLOBAL TOBACCO CONTROL POLICY DATA

Okinawa, Toyako, and Beyond: Progress on Health and Development

Dr. Collins Tabu 24 th April 2018 Nairobi, Kenya

Tuberculosis: Opportunities and Challenges for Achieving HIV Epidemic Control

Global Immunizations & UNICEF s Role Dr. Robin Nandy Principal Advisor & Chief of Immunizations UNICEF Headquarters

Market Updates: Routine Vaccine Introductions IPV. Vaccine Industry Consultation October 2018 UNICEF Supply Division

Ending mother to child transmission through community action. Ngashi Ngongo, MD, MPH Senior Health Advisor UNICEF New York

The Global Fund & UNICEF Partnership

HPV Vaccination Global policy perspectives Vacuna VPH Perspectivas de la política de vacunación mundial

Challenges and solutions in making evidence-based national vaccination policies and recommendations

DECLARATION ON ACCELERATION OF HIV PREVENTION EFFORTS IN THE AFRICAN REGION

Update on influenza maternal immunization. Joachim Hombach WHO Initiative for Vaccine Research

TT Procured by UNICEF

CEO Board report Seth Berkley MD CEO

A vaccine s journey: the many steps to saving lives

Innovative Finance: the power of innovation to save lives

Update on Meningococcal A Vaccine Development and Introduction

PLANNING & EVALUATION WORKBOOK. WEB: FACEBOOK:

PROGRESS REPORT ON CHILD SURVIVAL: A STRATEGY FOR THE AFRICAN REGION. Information Document CONTENTS

WHO Rotavirus Vaccine Update Dr. Fatima Serhan WHO/FWC/IVB/EPI

The MenAfrivac Experience A Successful Approach. Dr Bernard FRITZELL BFL conseils France

Global landscape analysis and literature review of 2 nd Year of Life immunization platform

What can be done against XDR-TB?

REPRODUCTIVE, MATERNAL, NEWBORN AND CHILD HEALTH (RMNCH) GLOBAL AND REGIONAL INITIATIVES

EBOLA SITUATION REPORT

Ending preventable maternal and child mortality

Development of a Group A meningococcal conjugate vaccine for sub-saharan Africa: clinical trial results

UNICEF Programme Updates

2. Treatment coverage: 3. Quality of care: 1. Access to diagnostic services:

Methodological issues in the use of anthropometry for evaluation of nutritional status

Report. 10 th Meeting of the Expert Review Committee (ERC) on Polio Eradication in Nigeria

CANCER FACT SHEETS: ALL CANCERS EXCLUDING NON-MELANOMA SKIN CANCER

PLANNING WORKBOOK 11 th Vaccination Week in the Americas

Measles and Rubella Global Update SAGE April 2018

Ethics Perspective of Immunisation Programs

HPV vaccine the global perspective

Update from the GAVI Alliance Seth Berkley, MD Chief Executive Officer

Update on Status of Wild Poliovirus Outbreak in Kenya. 9 th Meeting of the IMB 1-3 October 2013 London, UK

BEST PRACTICES IN MICROPLANNING FOR CHILDREN OUT OF THE HOUSEHOLD: AN EXAMPLE FROM NORTHERN NIGERIA

WHO Library Cataloguing-in-Publication Data. World health statistics 2011.

Development of polysaccharide-based conjugate vaccine against Haemophilus influenzaetype b infection

Expanded Programme on Immunization

FY2017 Q1: CORE Group Polio Project (CGPP) Quarterly Update

Global Polio Eradication & Endgame Strategy. December 2015

WHO Consultation on universal access to core malaria interventions in high burden countries: main conclusions and recommendations

FISCAL YEAR 2020 APPROPRIATIONS REQUESTS (updated ) USAID Global Health Programs (GHP) and State Department

POLIO ERADICATION IN THE AFRICAN REGION: PROGRESS REPORT. Information document EXECUTIVE SUMMARY

Sudan EPI Benefits From Polio Eradication Program

Transcription:

Maternal and Neonatal Tetanus Elimination by 2012 Yes, We Can! Global Immunization Meeting 18 th February 2009

OUTLINE Can we eliminate MNT by 2012? Can MNTE contribute to MDG4? Can TT-SIAs help to deliver more interventions? Can MNTE be sustained? Can we afford the cost?

Can we eliminate MNT by 2012?

Mix of strategies proven successful in protecting women against tetanus Immunize women ANC Outreach immunization sessions Supplemental Immunization Activities (SIAs) Improve Clean Delivery Coverage Needs structural / system changes Surveillance Case detection and case response

Bangladesh has eliminated neonatal tetanus as a cause of neonatal death 100 TT-SIAs Proportion on neonatal death due to tetanus (%) 90 80 70 60 50 40 30 20 10 0 1970 1975 1980 1985 1990 1995 2000 2005 2010 routine Year Source: published survey studies. Includes sub-national studies. TT2+ data from Bangladesh EPI/ JRF

37 Countries to be validated for MNT Elimination 2009-2010 (28 countries in Africa) 22 12 15 7 3 Source : UNICEF, WHO. Data as of 25 January 2009

Can MNTE contribute to MDG4?

78% Reduction in Neonatal Tetanus Deaths Between 1992 and 2004 700,000 600,000 500,000 580,000 515,000 490,000 NT deaths PAB 100 90 80 70 400,000 300,000 200,000 100,000 248,000 200,000 180,000 128,000? 60 50 40 30 20 10 coverage (%) 0 1990 1991 1992 1993 1994 Source: WHO estimates used for NT deaths and PAB 1997 2000 2002 2004 2006 2007 2008 0

Despite Global Progress, NT remains a major killer in some countries Source: Country Data: Countdown to 2015 The 2008 Report Source: Global Data: WHO Global Burden of Disease 2004 Update 2007

Can TT-SIAs help to deliver more interventions?

TT-SIAs target the poorest performing districts Myanmar district review Source: Myanmar EPI/ UNICEF Myanmar All data for 2005 So, Why only TT?

High coverages have been achieved for multiple interventions Sierra Leone 2007-2008 (All 13 Districts) No. of Districts having reached > 80% coverage, per intervention No. of districts 13 12 11 10 9 8 7 6 5 4 3 2 1 0 Round 1 Round 2 Round 3 Vit A TT Deworming Source: Sierra Leone EPI/ UNICEF Sierra Leone

Integrated campaigns may be risky for TT coverage

Can MNTE be sustained?

Maintaining MNT Elimination and Protecting all against tetanus Recommended doses: DPT 1-2-3 before one year 1 Td between 1 and 7 years (school entry) 1 Td between 12 and 15 years (beginning of adolescence) 1 Td at the beginning of adulthood Source: WHO Position Paper on Tetanus

Maintaining MNT Elimination and Protecting all against tetanus Recommended doses: DPT 1-2-3 before one year 1 Td between 1 and 7 years (school entry) 1 Td between 12 and 15 years (beginning of adolescence) 1 Td at the beginning of adulthood School-Based Immunization Source: WHO Position Paper on Tetanus

School Immunization: can reduce the need for adult doses Indonesia Source: NIP Indonesia, Data as of 15 September 2008

Primary School Attendance Levels offer opportunities for school-based immunization Sources: UNICEF: State of the World's Children 1999 and 2008

Maintaining MNT Elimination and Protecting all against tetanus Recommended doses: DPT 1-2-3 before one year 1 Td between 1 and 7 years (school entry) 1 Td between 12 and 15 years (beginning of adolescence) 1 Td at the beginning of adulthood Child Health Days

CHDs will be instrumental in maintaining TT protection levels Countries that implemented CHDs or Micronutrient events in 2008

CHDs will be instrumental in maintaining TT protection levels Countries that implemented CHDs or Micronutrient events in 2008 Countries that require TT-SIAs to achieve &/ or maintain MNT Elimination

Maintaining MNT Elimination and Protecting all against tetanus Recommended doses: DPT 1-2-3 before one year 1 Td between 1 and 7 years (school entry) 1 Td between 12 and 15 years (beginning of adolescence) 1 Td at the beginning of adulthood Meningitis A Vaccine

Sustaining TT protection through meningococcal A conjugate vaccine in countries at risk Fraction (%) with protective (>.1 IU/ml) anti-tetanus antibody 4 weeks after PsA-TT or PS vaccine Site Mali Niakhar Basse PsA- TT 98.5 100 100 2-10 PS 57.6 77.4 78.8 Age in years PsA- TT 98.5 100 100 11-17 PS 37.5 56.3 44.1 PsA- TT 94.0 100 93.8 18-29 PS 60.6 61.3 33 Total 99.5 71.1 99.5 45.9 95.9 52.1

Men A conjugate vaccine introduction will boost TT immunity to all Men A conjugate vaccine introduction 2009 2010 2011 2012 2013-2015

Can we afford the cost?

3 TT-SIAs at a marginal cost of $1.80 Subunit breakdown of $1.80 (shown as % of total cost) Supervision and monitoring 7% NT surveillance 2% Clean delivery promotion 6% Vaccine & injection supplies 29% Transport 19% Health workers stipends 11% Note: Total cost varies between countries Advocacy & social mobilization 13% Planning and Training 13%

TT-SIAs in 18 out of 26 countries fully funded in 2009 Source: WHO UNICEF MNT Collected Data, 2009. Data as of February 2009. TT-SIAs fully funded TT-SIAs not fully funded MNT Eliminated or TT-SIAs not planned in 2009 The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. WHO 2008. All rights reserved

US $241 million shortfall, US $65 million when excluding India and Nigeria 120 100 US $ (in millions) 80 60 40 50 87 89 20 0 39.5 30 12 5 5 2008 2009 2010 2011 2012 Funding gap in India and Nigeria Funding gap in all countries excluding India and Nigeria Met Needs 3 Source: WHO UNICEF estimates

18 Countries face funding shortfalls today 14 12 15 0 0

Donor commitment: 1999-2008: US$ 186 million raised Donor UNICEF Nat Coms: Cash (BMGF - $36m, RMHC-$5m) Bilateral Contributions Other contributions, governments UNICEF Discretionary funds GAVI/IFFIm funds BD P&G Pampers: (received) (pledged) TOTAL Amount $ 81.2m $ 66.2m $ 10.2m $ 8.0m $ 5.0m $ 61.6m $15m $ 5.0m $ 15.0m $186m

Innovative Approaches in Fund Raising Private-public partnerships Cause-related marketing (1 pack = 1 vaccine) Local Celebrities as Ambassadors for UNICEF Micro-gifts Unprecedented media exposure for MNTE Fund-raising Concerts

MNT Elimination by 2012 Yes, We Can!!

Alone we can go fast, All together we can go far! National MOH s (African proverb)